Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03315923
Recruitment Status : Completed
First Posted : October 20, 2017
Last Update Posted : May 23, 2019
Sponsor:
Information provided by (Responsible Party):
Vahid Shaygannejad, Isfahan University of Medical Sciences

Brief Summary:
The purpose of this study is to compare expanded disability status scale, annualized relapse rate, Gad-enhanced brain lesions, and side effects after administration of rituximab and glatiramer acetate among patients with active secondary progressive multiple sclerosis during a one year follow up through a randomized clinical trial.

Condition or disease Intervention/treatment Phase
Secondary Progressive Multiple Sclerosis Drug: Rituximab Drug: Glatiramer Acetate Phase 2 Phase 3

Detailed Description:

Multiple sclerosis (MS) is an autoimmune inflammatory demyelinative disease of central nervous system. Active secondary progressive MS means progressive accumulation of disability after an initial relapsing course which is also associated with clinical relapses and/or new/enlarged Gad-enhanced brain lesions. This form of the disease leads to high rates of morbidity and mortality among patients. Different immunosuppressive and immunomodulatory agents are recommended by researchers to decrease relapses and improve disability among MS patients. The effect of these medications on different phenotypes of MS are mostly investigated solely and very small number of comparative studies are conducted to evaluate the superiority of these medications on each other.

Glatiramer acetate is one of the known MS medications which is being used to control relapses from a long time ago and different clinical trials have shown its partial efficacy among MS patients. On the other hand, rituximab is one of the medications which is recently suggested for treatment of MS and currently phase II clinical trials are conducted to evaluate the efficacy of this medication among patients. As previously stated, there is a lack of clinical trials to compare the efficacy of suggested medications among secondary progressive patients. To fill this gap, we aimed to compare the efficacy of these two medications on disability, annualized relapse rate, and Gad-enhanced brain lesions among patients with active secondary progressive MS through a randomized clinical trial during a one-year follow-up period.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 84 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Comparison of Expanded Disability Status Scale, Gad-enhanced Brain Lesions, Annualized Relapse Rate, and Side Effects Between Active Secondary Progressive Multiple Sclerosis Patients on Rituximab and Glatiramer Acetate
Actual Study Start Date : December 1, 2017
Actual Primary Completion Date : February 1, 2019
Actual Study Completion Date : March 1, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Rituximab
Patients in this group will receive 1g of rituximab in 500 cc normal saline serum through intravenous infusion as one treatment course. The treatment course will be repeated in 6 months. Along with rituximab, 100 mg methylprednisolone, 10 mg chlorpheniramine, and 500 mg acetaminophen will also be injected to decrease side effects of rituximab.
Drug: Rituximab
Patients will receive 1 g of rituximab (two vials of Zytux 500 mg/50 ml) in 500 cc normal saline serum through intravenous infusion as one treatment cycle. This cycle will be repeated every 6 months. Along with rituximab, patients will receive 100 mg of methylprednisolone, 10 mg of chlorpheniramine, and 500 mg of acetaminophen. Before each cycle, patients will be evaluated regarding complete blood count (CBC)-diff, blood urea nitrogen (BUN), Cr, and liver function tests.
Other Name: Zytux®

Experimental: Glatiramer acetate
Patients in this group will receive 40 mg of glatiramer acetate three times per week through subcutaneous injection.
Drug: Glatiramer Acetate
Patients will receive 40 mg of glatiramer acetate three times per week through subcutaneous injection. Patients will undergo electrocardiography before starting the treatment to find any abnormal finding. Also, lab tests will be checked for them prior to the treatment, including CBC-diff, BUN, Cr, and liver function tests.
Other Name: Osvimer®




Primary Outcome Measures :
  1. Disability measured by Expanded Disability Status Scale [ Time Frame: one year ]
    expanded disability status scale will be measured in the baseline and after 12 months of intervention. This scale measures the disability of patients with a score, ranging from 0 (normal neurological exam) to 10 (death due to MS). This score is assigned to the patient by the neurologist and after neurological examination. The patient will be given a score in this scale according to the observed disability. The scores will be compared at the end of study.


Secondary Outcome Measures :
  1. Adverse Drug Reactions [ Time Frame: one year ]
    adverse drug reactions will be observed closely and reported during the intervention. We will compare the number of adverse drug reactions in two groups. Also, adverse drug reactions will be described by details in each group.

  2. number of Gadolinium-enhanced brain lesions and neuroimaging findings [ Time Frame: one year ]
    patients will undergo brain MRI before and after the study and number of Gad-enhanced brain lesions will compared before and after intervention.

  3. Annualized relapse rate [ Time Frame: one year ]
    annualized relapse rate will be measured in the baseline (according to patients' history in the last year) and after 12 months of intervention.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • age between 18 and 55 years old
  • diagnosis of active secondary progressive multiple sclerosis based on the latest McDonald criteria in 2010
  • experiencing at least one relapse during the last year
  • expanded disability status scale ≤5
  • diagnosis of secondary progressive MS for at least one year
  • maintaining pregnancy prevention methods for women in reproductive ages
  • filling the written informed consent prior to enrollment

Exclusion Criteria:

  • diagnosis of other subtypes of MS, including relapsing-remitting MS and primary progressive MS and inactive form of the disease
  • experiencing relapse during the 30 days before starting the study
  • receiving systemic corticosteroid therapy during the last 30 days
  • undergoing plasmapheresis or receiving intravenous immunoglobulin during the last 1 months
  • history of other demyelinative diseases of central nervous system such as neuromyelitis optica spectrum disorders
  • history of other autoimmune diseases such as systemic lupus erythematosus, sjogren's syndrome, antiphospholipid syndrome, and behcet's disease
  • presence of chronic or recurrent infections such as hepatitis B, hepatitis C, or syphilis
  • pregnancy or lactation
  • receiving live attenuated viral vaccines during the last 4 weeks
  • history of cardiac arrhythmia, angina pectoris, or other cardiac diseases
  • history of immunodeficiency syndromes such as HIV
  • white blood cell count <2500 or lymphocyte count <400
  • history of brain and spinal malignancies
  • history of severe allergic reactions or anaphylaxis to monoclonal antibodies
  • presence of active bacterial, viral, fungal, mycobacterial, or other infections
  • alcohol or drug abuse during the last two years
  • unable to undergo MRI
  • presence of uncontrolled cardiac, respiratory, renal, hepatic, endocrine, or gastrointestinal disease
  • presence of encephalopathy due to infectious (such as herpes, syphilis, ...) or metabolic (vitamin B12 deficiency) reasons
  • history of bone marrow transplant, whole body radiotherapy, or other treatments leading to reduction of lymphocytes
  • Cr>1.4 in women and >1.6 in men
  • aspartate transaminase and alanine transaminase 2.5 times higher than the normal amount
  • platelet count <100000
  • Hb <8.5

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03315923


Locations
Layout table for location information
Iran, Islamic Republic of
Kashani Hospital
Isfahan, Iran, Islamic Republic of, 8174673461
Sponsors and Collaborators
Isfahan University of Medical Sciences
Investigators
Layout table for investigator information
Study Chair: Vahid Shaygannejad, M.D. Isfahan University of Medical Sciences

Publications:

Layout table for additonal information
Responsible Party: Vahid Shaygannejad, Professor of Neurology, Isfahan University of Medical Sciences
ClinicalTrials.gov Identifier: NCT03315923     History of Changes
Other Study ID Numbers: 396514
First Posted: October 20, 2017    Key Record Dates
Last Update Posted: May 23, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: We may share the individual participant data (anonymously) on request of qualified investigators.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Vahid Shaygannejad, Isfahan University of Medical Sciences:
Active secondary progressive Multiple Sclerosis
Glatiramer acetate
Rituximab
Comparative study
Disability
Randomized clinical trial
Annualized relapse rate
Additional relevant MeSH terms:
Layout table for MeSH terms
Glatiramer Acetate
Neoplasm Metastasis
Multiple Sclerosis
Multiple Sclerosis, Chronic Progressive
Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Neoplastic Processes
Neoplasms
Rituximab
(T,G)-A-L
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Adjuvants, Immunologic
Immunosuppressive Agents